Pronunciation: ri-MAN-ta-deen HYE-droe-KLOR-ide
Class: Antiviral agent
- Tablets 100 mg
Inhibits viral replication cycle in various strains of influenza A virus.
Well absorbed. C max is 74 ng/mL (single dose). T max is 6 h (single dose).
Protein binding is 40%, mainly albumin.
Extensively metabolized in the liver to 3 hydroxylated metabolites.
Eliminated in the urine (less than 25% as unchanged drug). Half-life is 25.4 h (single dose).
Special PopulationsRenal Function Impairment
C max , AUC 0 to Tau , and half-life increased by 75%, 81%, and 49%, respectively, in patients with severe renal impairment (CrCl 5 to 29 mL/min). There was a 1.6-fold increase in half-life and 40% decrease in apparent Cl of rimantadine in hemodialysis patients. Half-life was slightly prolonged (increased 18% or less) and there was no clinically relevant difference in C max and AUC in patients with mild or moderate renal impairment.Hepatic Function Impairment
AUC was about 3-fold larger, elimination half-life was about 2-fold longer, and apparent Cl was 50% lower in patients with severe hepatic impairment.Elderly
In patients older than 70 years of age, the average AUC, peak concentrations, and elimination half-life at steady state were 20% to 30% higher.Children
Pharmacokinetic profile in children not established.
Indications and UsageAdults
Prophylaxis and treatment of infection caused by various strains of influenza A virus.Children
Prophylaxis against influenza A virus.H1N1 recommendations
Per the CDC recommendations for treatment and chemoprophylaxis of H1N1 influenza A (swine flu) virus infection, refer to the oseltamivir and zanamivir summary monographs. The H1N1 virus is resistant to the antiviral medication rimantadine. For more information, refer to the CDC guidelines at http://www.cdc.gov/h1n1flu/recommendations.htm .
Treatment of influenza A virus in children.
Hypersensitivity to drugs in adamantine class, including rimantadine and amantadine.
Dosage and AdministrationProphylaxis and Treatment
PO 100 mg twice daily. For the treatment of influenza A, initiate treatment as soon as possible, preferably within 48 h after onset of signs and symptoms of influenza A infection, and continue for approximately 7 days after initial onset of symptoms.Elderly Patients, Severe Hepatic Impairment, and Severe Renal Impairment (CrCl less than 30 mL/min)
Children 10 y of age and older
PO 100 mg twice daily.Children 1 to 9 y of age
PO 5 mg/kg once daily (max, 150 mg).
- An oral suspension (10 mg/mL) may be compounded from the oral tablets using Ora-Sweet for patients who have difficulty swallowing tablets or when a dose lower than 100 mg is needed (see manufacturer's prescribing information for further directions).
Store between 59° and 86°F. Compounded oral suspension is stable for 14 days at ambient room temperature.
Drug InteractionsAcetaminophen, aspirin
Decreased C max and AUC of rimantadine. However, based on the magnitude of the interaction, a clinically important consequence is unlikely.Cimetidine
Increased rimantadine serum concentration caused by decreased Cl. However, based on the magnitude of the interaction, a clinically important consequence is unlikely.Live vaccine
Because of potential interference between these products, do not give live attenuated intranasal influenza vaccine until 48 h after cessation of rimantadine, and do not administer rimantadine until 14 days after cessation of live attenuated intranasal influenza vaccine.
Insomnia (3%); dizziness, impaired concentration, nervousness (2%); asthenia, fatigue, headache (1%).
Nausea (3%); anorexia, dry mouth, vomiting (2%); abdominal pain (1%).
Monitor patients with any degree of renal or hepatic insufficiency for adverse reactions and adjust the dose as needed.
Category C .
Undetermined. Do not administer to breast-feeding mothers.
Prophylaxis studies have not been performed in children younger than 1 y of age. Safety and effectiveness for the treatment of symptomatic influenza infection have not been established in children younger than 17 y of age.
CNS symptoms may occur more frequently.
Use with caution. Monitor patients for adverse reactions and adjust the dose as needed.
Use with caution.
Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as complications during influenza; rimantadine has not been shown to prevent such complications.
Increased incidence of seizures reported in patients with seizure history who received the related drug amantadine.
Consider transmission of resistant virus when treating patients with contacts who are at a high risk of influenza A illness.
No information reported.
- Advise patients to use this medication for the full course of treatment.
- Inform patients that this medication only works on certain types of flu and that it does not treat other viral infections (eg, common cold).
- Advise patients to not take this medication until 2 wk after they receive a live intranasal flu vaccine, and to not receive a live nasal flu vaccine within 48 h after they stop taking this medication.
- Inform patients using the compounded oral suspension to shake well prior to administration.
Copyright © 2009 Wolters Kluwer Health.
More Rimantadine Hydrochloride resources
- Rimantadine Hydrochloride Monograph (AHFS DI)
- Rimantadine Prescribing Information (FDA)
- Flumadine Prescribing Information (FDA)
- Flumadine Concise Consumer Information (Cerner Multum)
- Flumadine MedFacts Consumer Leaflet (Wolters Kluwer)
- Flumadine Advanced Consumer (Micromedex) - Includes Dosage Information